Clemson names technology development director at CUBEInC

Published: February 11, 2013

Michael J. Gara image by: Clemson University

CLEMSON — Michael J. Gara has been named director of technology development for the Clemson University Biomedical Engineering Innovation Campus (CUBEInC).

Located in Greenville, CUBEInC strives to develop high-impact medical technology and devices for disease management, then oversee the transfer of this technology from bench to bedside.

“Clemson has a long and rich history in medical technology commercialization,” Gara said. “Upstate South Carolina, nationally known for its high quality of life and business-friendly environment, is home to more corporate headquarters than any other region of the state. CUBEInC is a vibrant constituent of these knowledge economies.”

At CUBEInC, clinically driven technology and treatment methods are developed and health system optimization practiced with an aim to help practitioners provide improved health-care delivery.

According to Gara, this facility “stimulates closer collaboration between clinicians and health-care providers from the Greenville Hospital System with Clemson’s engineering and scientific talent. As a result, focused research projects have a meaningful clinical impact and are attractive to the industry and investors as new product opportunities and startup life science companies.”

Employed in the pharmaceutical and biotechnology industries for more than 30 years, Gara has worked for numerous pharmaceutical companies in the areas of research and development, manufacturing, product development and business development. In addition, Gara has managed translational research programs in biomedical engineering at major universities across the United Sates.

Currently, Gara’s position with Clemson University’s life science incubator involves the creation, funding and commercialization of life science companies in Upstate South Carolina.

“I look forward to many future successes as Clemson research continues to have a profound impact on patients’ lives,” Gara said.

END